latest news releases from the newsroom
Questcor Board Increases Share Repurchase Program Authorization
UNION CITY, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that its Board of Directors has increased the Company's common share repurchase program authorization by an additional 6.5 million shares. In late February 2008, the Board authorized the repurchase of up to 7.0 million shares. Under this original authorization, as of June 1, 2009, the Company has repurchased approximately 5.9 million shares, including 1.3 million in the first quarter of 2009, and 1.0 million to date during the second quarter of 2009. The additional 6.5 million share authorization represents approximately 10 percent of the Company's outstanding common stock. As of March 31, 2009, Questcor had 64.6 million common shares outstanding.
Talon Therapeutics, Inc.
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care, presented updated data for Marqibo(r) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse and data from metastatic uveal melanoma at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 29-June 2, 2009 in Orlando, Florida.